Ratings Ocumension Therapeutics

Equities

1477

KYG674111011

Market Closed - Hong Kong S.E. Other stock markets 04:08:16 2024-04-24 am EDT			5-day change	1st Jan Change
6.03 ^HKD	+1.17%		+2.20%	-9.73%

Apr. 15	Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug	MT
Apr. 15	Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
OCUMENSION THERAPEUTICS	-9.73%	528M	-
ELI LILLY AND COMPANY	+27.92%	672B	C+
NOVO NORDISK A/S	+27.03%	570B	B
JOHNSON & JOHNSON	-4.59%	360B	C+
MERCK & CO., INC.	+16.38%	321B	B-
ABBVIE INC.	+9.39%	300B	C+
ASTRAZENECA PLC	+7.42%	217B	B+
NOVARTIS AG	+5.86%	199B	B-
ROCHE HOLDING AG	-8.51%	204B	A+
PFIZER, INC.	-8.58%	149B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes